You are here: Industry Insights > IVIG

News List

Children with severe MIS-C do better when treated initially with combined IVIG and steroids firstwordpharma
June 17, 2021
When children started getting sick with a multisystem inflammatory syndrome (MIS-C) in the wake of COVID-19, physicians most often turned to two treatments: IV immunoglobulin (IVIG), because of MIS-C's similarities with Kawasaki disease, and steroids.
ADMA Receives FDA Approval for Increased IVIG Production Scale contractpharma
April 30, 2021
ADMA Biologics, an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, has received approval from the FDA for the company’s expanded manufacturing process, enabling ...
FDA Approves ADMA Biologics Increased IVIG Production contractpharma
April 29, 2021
ADMA Biologics, Inc., a commercial biopharmaceutical company dedicated to specialty plasma-derived biologics, received approval from the U.S. FDA for the company’s expanded manufacturing process, enabling fractionation and purification of a ...
Octapharma launches phase 3 superiority study for PANS pharmaceutical-business-review
September 08, 2020
Octapharma has launched a phase 3, multicenter superiority study to compare the effectiveness of PANZYGA (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome.
Octapharma USA extends funding for Covid-19 study following positive preliminary research data pharmaceutical-business-review
June 08, 2020
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic ...
Octapharma Extends Funding for COVID-19 Study contractpharma
June 04, 2020
Study evaluating using IVIG as investigational coronavirus treatment for adults experiencing respiratory failure.
Octapharma Supports New COVID-19 Trial contractpharma
April 17, 2020
Aims to assess if Intravenous Immunoglobulin (IVIG) can halt coronavirus progression to respiratory failure.
ADMA Biologics' shares surge after intravenous immune globulin drug product Asceniv gains FDA approval firstwordpharma
April 02, 2019
According to ADMA, the product's label will include a boxed warning about potential thrombosis and renal dysfunction or failure.